Jiangsu HengRui Medicine
As of the edition of 20 October 2026, Jiangsu HengRui Medicine runs 161 drugs, 1 of them marketed; it is on route A at 8 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Jiangsu HengRui Medicine was renamed in 2022.
The records place 5 company names in this family.
- Jiangsu HengRui Medicine Co., Ltd.: renamed in 2022
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 103 |
| Went quiet | 8 |
| Stopped | 21 |
| Status not established | 28 |
| Total | 161 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Remimazolam | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 8 targets, route B at 0 targets.
All 8 rows on route A or B
In the product8 company-target rows on route A or B; 5 are not shown here, and no score is.
See all 8 targets where Jiangsu HengRui Medicine needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 177 trials led
- Nutrition and metabolism: 90 trials led
- Hormones: 72 trials led